J&J Reaches Tentative Deal over Risperdal Marketing
09:33 EDT 3 Aug 2012 | PharmPro
Johnson & Johnson revealed in a regulatory filing that it reached an "agreement in principle" with the U.S. Department of Justice and some states to settle investigations into marketing practices for Risperdal (risperidone) and two other products..
Original Article: J&J Reaches Tentative Deal over Risperdal Marketing
More From BioPortfolio on "J&J Reaches Tentative Deal over Risperdal Marketing"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
